clinical trial · NCT05879744
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
NHLNHL, Relapsed, AdultCLN-978
brief summary
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
started
May 31, 2023
primary completion
Nov 1, 2026
completion
Apr 1, 2027
last updated
May 2, 2024
official title
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol